AstraZeneca
AZN
722 hedge funds and large institutions have $22.3B invested in AstraZeneca in 2020 Q3 according to their latest regulatory filings, with 124 funds opening new positions, 262 increasing their positions, 214 reducing their positions, and 64 closing their positions.
94% more first-time investments, than exits
New positions opened: 124 | Existing positions closed: 64
22% more repeat investments, than reductions
Existing positions increased: 262 | Existing positions reduced: 214
8% more funds holding
Funds holding: 668 → 722 (+54)
1% more call options, than puts
Call options by funds: $365M | Put options by funds: $362M
0.79% less ownership
Funds ownership: 16.31% → 15.52% (-0.79%)
1% less capital invested
Capital invested by funds: $22.7B → $22.3B (-$315M)
45% less funds holding in top 10
Funds holding in top 10: 11 → 6 (-5)
Top Buyers
| 1 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
+$209M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$113M |
| 3 |
GQG Partners
Ft. Lauderdale,
Florida
|
+$87.2M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$50.1M |
| 5 |
Jane Street
New York
|
+$42.1M |
Top Sellers
| 1 |
Jennison Associates
New York
|
-$450M |
| 2 |
Dodge & Cox
San Francisco,
California
|
-$220M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$187M |
| 4 |
Renaissance Technologies
New York
|
-$152M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$136M |
AZN Hedge Fund Activity: Q3 2020 in Review
722 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q3 2020, worth a combined $22.3B — down 1.4% from $22.7B a quarter earlier.
Buyers outnumbered sellers: 124 funds opened new AZN positions and 64 closed out — a net gain of 60 holders — while 262 added to existing stakes and 214 trimmed.
The largest buyer was CIBC Private Wealth Group, adding an estimated $209M. The largest seller was Jennison Associates, cutting an estimated $450M.
- 722 institutional investors held AstraZeneca (AZN) as of Q3 2020, up from 668 in Q2 2020.
- Funds reported $22.3B of AstraZeneca stock for Q3 2020, down 1.4% quarter-over-quarter.
- 124 funds opened new AstraZeneca positions in Q3 2020 and 64 closed out, a net change of +60 holders.
- The largest AstraZeneca buyer in Q3 2020 was CIBC Private Wealth Group, an estimated $209M added.
- The largest AstraZeneca seller in Q3 2020 was Jennison Associates, an estimated $450M sold.
Based on aggregated 13F filings for Q3 2020.